Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12882
Title: Sites of actions of alpha 2 agonists in the brain and periphery.
Austin Authors: Louis, William J ;Jarrott, B;Conway, Elizabeth L
Affiliation: Clinical Pharmacology and Therapeutics Unit, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 24-Feb-1988
Publication information: The American Journal of Cardiology; 61(7): 15D-17D
Abstract: Alpha 2 agonists including rilmenidine, clonidine and alpha methylnoradrenaline all seem to have a predominantly central action in lowering blood pressure. Studies using the peripheral decarboxylase inhibitor alpha-methyldopa hydrazine in both experimental animals and humans support the predominant central action of the active metabolite of methyldopa, alpha methylnoradrenaline. Comparative studies on the antihypertensive potency of selective alpha 2 agonists like rilmenidine, guanfacine, clonidine and lofexidine suggest that the relative ability to bind to alpha 1 and alpha 2 adrenoceptors is not critical but the ability to enter the central nervous system is essential for antihypertensive efficacy.
Gov't Doc #: 2894151
URI: http://ahro.austin.org.au/austinjspui/handle/1/12882
URL: https://pubmed.ncbi.nlm.nih.gov/2894151
Type: Journal Article
Subjects: Adrenergic alpha-Agonists.pharmacokinetics.pharmacology
Animals
Binding Sites
Blood Pressure.drug effects
Brain.drug effects.metabolism
Carbidopa.pharmacokinetics.pharmacology
Clonidine.pharmacokinetics.pharmacology
Decarboxylation
Methyldopa.pharmacokinetics.pharmacology
Neurotransmitter Agents.metabolism
Radioligand Assay
Receptors, Adrenergic, alpha.metabolism.physiology
Vasoconstriction.drug effects
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.